The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the initial results from a cohort of the UK Myeloma Research Alliance (UKMRA) RADAR trial (ISRCTN46841867), which is evaluating the efficacy of isatuximab, bortezomib, lenalidomide, dexamethasone, and cyclophosphamide (Isa-VRDc) induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk myeloma. Dr Ramasamy highlights that the study demonstrated activity in this high-risk patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are so pleased to present the first clinical results of the RADAR trial. I, on behalf of the UK Myeloma Research Alliance and co-investigators, presented results of the high-risk phase 2 study. On version 4 of the high-risk arm, we recruited 70 patients who were given R-CyBorD induction for one cycle, had their genetic tests, and if they had two or more high-risk features as defined by the IMWG 2020, entered the high-risk arm and received isotuximab R-CyBorD, three more cycles, a single stem cell transplant, and VRd-R bordexomib consolidation and VRd-R maintenance, also known as lenalidomide, was not mentioned but ESA likely refers to lenalidomide and was replaced with the more common term for the combination, The study was looking at progression-free survival as the primary endpoint...
We are so pleased to present the first clinical results of the RADAR trial. I, on behalf of the UK Myeloma Research Alliance and co-investigators, presented results of the high-risk phase 2 study. On version 4 of the high-risk arm, we recruited 70 patients who were given R-CyBorD induction for one cycle, had their genetic tests, and if they had two or more high-risk features as defined by the IMWG 2020, entered the high-risk arm and received isotuximab R-CyBorD, three more cycles, a single stem cell transplant, and VRd-R bordexomib consolidation and VRd-R maintenance, also known as lenalidomide, was not mentioned but ESA likely refers to lenalidomide and was replaced with the more common term for the combination, The study was looking at progression-free survival as the primary endpoint. 88% of patients were progression-free at 18 months, showing clear activity of this high-risk pathway. So there are further versions of the high-risk pathway that we have recruited to in the RADAR study and we have recruited another 50 patients in this high-risk pathway and these results we would share in due course in further conferences.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
